Super-enhancers seen as ‘Rosetta Stone’ for dialog between genes and disease
CAMBRIDGE, Mass. – Having recently discovered a set of powerful gene regulators that control cell identity in a few mouse and human cell types, Whitehead Institute scientists are now showing that these regulators—which they named “super-enhancers”—act across a vast array of human cell types and are enriched in mutated regions of the genome that are closely associated with a broad spectrum of diseases.
The findings, published online today by the journal Cell, suggest that these super-enhancers, first described in Cell several months ago by Whitehead Member Richard Young, could ultimately play important roles in disease diagnostics and therapeutics.
In April, Young reported that while the total number of genetic control elements is likely in the millions, only a few hundred super-enhancers regulate the key genes that give each cell its unique properties and functions. At the time, Young hinted that the discovery, which was based on work primarily in embryonic stem cells, would help to solve the regulatory circuitry of all human cells. This latest research represents a significant step toward that goal, producing a catalog of super-enhancers in nearly 100 human cell and tissue types.
“We’ve gone from a few cells to a broad swath of human cell types to create this resource and make it available to the biomedical research community,” says Young, who is also a professor of biology at MIT.
Young notes that the striking finding of the new study is that beyond their roles in control of healthy cells, super-enhancers are involved in regulating the function—and dysfunction—of diseased cells.
“We were surprised that for so many different diseases, mutations associated with the disease occur in super-enhancers,” says postdoctoral scientist Brian Abraham, an author of the study. Indeed, he and other researchers in Young’s lab found in disease-relevant cell types genetic mutations associated with Alzheimer’s disease, diabetes, and many autoimmune diseases in genomic regions under the control of specific super-enhancers.
The researchers also found super-enhancers operating in particularly insidious fashion across a broad spectrum of cancers, observing cancer cells assembling their own super-enhancers to overproduce malevolent oncogenes that drive such cancer hallmarks as hyperproliferation, invasion, and metastasis. Young believes that identifying, mapping, and disrupting super-enhancers could alter the way cancers are managed in the clinic.
“When we focus on personalized medicine for cancer patients, super-enhancers could serve as useful biomarkers for tracking and understanding the evolution of a person’s cancer,” says Young. “Ultimately, super-enhancers may well become important targets for therapeutic intervention.”
This work was supported by grants from the National Institutes of Health (grants HG002668, CA109901, and CA146445).
Richard Young’s primary affiliation is with Whitehead Institute for Biomedical Research, where his laboratory is located and all his research is conducted. He is also a professor of biology at Massachusetts Institute of Technology.
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., ... & Young, R. A. (2013). Super-enhancers in the control of cell identity and disease. Cell, 155(4), 934-947.
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., ... & Young, R. A. (2013). Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell, 153(2), 307-319.
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., ... & Young, R. A. (2013). Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell, 153(2), 320-334.
Communications and Public Affairs